Resultados de supervivencia del cáncer colorrectal metastásico (CCRm) en una cohorte de una práctica en Medellín, Colombia
Survival Outcomes of Metastatic Colorectal Cancer (mCRC) in A Single Practice Cohort in Medellín, Colombia
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Therapy for mCRC is based on surgery, cytotoxic chemotherapy, and biologic agents. In randomized clinical trials, median progression-free survival (PFS) and overall survival (OS) hover around 10mo and 29mo, respectively. There are no published results on survival outcomes of patients with mCRC in Colombia. Objective: Describe the survival outcomes of patients with mCRC treated by Mauricio Lema in Medellín, Colombia. Methods: This is a retrospective, case series (2008-2020) of mCRC, ≥18 years old, treated with systemic therapy for metastatic disease, and ≥3-month follow-up. Stratification factors included: use of biologic (anti-VEGF or anti-EGFR) plus chemotherapy in 1st-Line (yes/no) and metastasectomy (yes/no). Survival analyses were evaluated using Kaplan- Meier curves. Results from the general population are described, and they are also discriminated against by the use of a biological agent in the first-line of systemic therapy. Results: 89 patients with mCRC were included. The Median follow-up was 35 months (IQR: 21-57). Median PFS and OS were 12.1mo (95%CI: 10.4-13.8) and 29.3mo (95%CI: 23.2-34.4), respectively. Median OS in patients receiving biologics was 28.8mo (95%CI: 22.1 – 35.6) vs 33.7mo (95%CI: 16.4 – 51.0) in the chemo-only group (p=0.01). Median OS in the metastasectomy and non-metastasectomy groups were 36.1 (95% CI: 26.5 - 45.7) and 25.0 months (95% CI: 15.4 - 34.5), respectively (NS). Conclusion: In this case series of patients’ survival outcomes were similar to thosereported in large phase III trials. A small sample size precludes any conclusion as to the impact of biologic agents on survival in this study.
Article visits 460 | PDF visits 314
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;0(0):1–41. Available from: https://doi.org/10.3322/caac.21660.
- Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91. Available from: https://doi.org/10.1136/gutjnl-2015-310912.
- Arnold M, Abnet CC, Neale RE, Vignat J, Giovannucci EL, McGlynn KA, et al. Global Burden of 5 Major Types of Gastrointestinal Cancer. Gastroenterology [Internet]. 2020;159(1):335-349.e15. Available from: https://doi.org/10.1053/j.gastro.2020.02.068
- International Agency for Research on Cancer. GLOBOCAN 2020: Estimated cancer incidence, mortality and prevalence worldwide in 2020 [Internet]. 2020. Available from: https://gco.iarc.fr/today/home
- Fakih MG. Metastatic colorectal cancer: Current state and future directions. J Clin Oncol. 2015;33(16):1809–24. Available from: https://doi.org/10.1200/JCO.2014.59.7633
- Campo-Sánchez SM, Camargo-Trillos J, Calle-Ramírez JA, Gómez-Wolff LR, Sánchez-Patiño LA, García-García HI. Colorectal cancer survival at an oncologic center in Colombia. A historic cohort study. Rev Gastroenterol Mex. 2019;84(2):174–84. Available from: https://doi.org/10.1016/j.rgmx.2018.04.002.
- Ciombor KK, Bekaii‐Saab T. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Oncologist. 2018;23(1):25–34. Available from: https://doi.org/ 10.1634/theoncologist.2017-0203.
- Stein A, Folprecht G. Immunotherapy of Colon Cancer. Oncol Res Treat. 2018;41(5):282–5. Available from: https://doi.org/10.1159/000488918.
- Liu Z, Zhang L, Xu X, Pan Y, Chen D, Liu D, et al. Current status of immunotherapy for metastatic colorectal cancer. Cancer Res Prev Treat. 2020;47(12):925–30. Available from: https://doi.org/10.3971/j.issn.1000-8578.2020.20.0864.
- Chakedis J, Schmidt CR. Surgical Treatment of Metastatic Colorectal Cancer. Surg Oncol Clin N Am [Internet]. 2018;27(2):377–99. Available from: https://doi.org/10.1016/j.soc.2017.11.010
- Cortés A, Eduardo Bravo L, Stella García L, Collazos P. Incidencia, mortalidad y supervivencia por cáncer colorrectal en Cali, Colombia, 1962-2012. (Spanish). Color cancer Incid Mortal Surviv Cali, Colomb 1962-2012 [Internet]. 2014;56(5):457–64. Available from: http://search.ebscohost.com/login.aspx?direct=true&db=bth&AN=98909692&lang=es&site=ehost-live.
- Bohorquez M, Sahasrabudhe R, Criollo A, Sanabria-Salas MC, Vélez A, Castro JM, et al. Clinical manifestations of colorectal cancer patients from a large multicenter study in Colombia. Med (United States). 2016;95(40). Available from: https://doi.org/10.1097/MD.0000000000004883.
- Uribe C, Osma S, Herrera V. Cancer incidence and mortality in the Bucaramanga metropolitan area, 2003-2007. Colomb Med. 2012;43(4):290–7. Available from: https://doi.org/10.25100/cm.v43i4.1196.
- Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer a randomized clinical trial. JAMA - J Am Med Assoc. 2017;317(23):2392–401. Available from: https://doi.org/10.1001/jama.2017.7105.
- Heinemann V, Weikersthal LF Von, Decker T, Kiani A, Vehling-kaiser U, Scholz M, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–75. Available from: https://doi.org/10.1016/S1470-2045(14)70330-4.
- Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): Long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. Available from: https://doi.org/10.1016/S1470-2045(13)70447-9.
- Aderka D, Stintzing S, Heinemann V. Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncol [Internet]. 2019;20(5):e274–83. Available from: http://dx.doi.org/10.1016/S1470-2045(19)30172-X.
Information
